Unknown

Dataset Information

0

LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.

ABSTRACT: Deficiency in DNA double-strand break (DSB) repair mechanisms has been widely exploited for the treatment of different malignances, including homologous recombination (HR)-deficient breast and ovarian cancers. Here we demonstrate that diffuse large B cell lymphomas (DLBCLs) expressing LMO2 protein are functionally deficient in HR-mediated DSB repair. Mechanistically, LMO2 inhibits BRCA1 recruitment to DSBs by interacting with 53BP1 during repair. Similar to BRCA1-deficient cells, LMO2-positive DLBCLs and T cell acute lymphoblastic leukemia (T-ALL) cells exhibit a high sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Furthermore, chemotherapy and PARP inhibitors synergize to inhibit the growth of LMO2-positive tumors. Together, our results reveal that LMO2 expression predicts HR deficiency and the potential therapeutic use of PARP inhibitors in DLBCL and T-ALL.

SUBMITTER: Parvin S 

PROVIDER: S-EPMC6752209 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Deficiency in DNA double-strand break (DSB) repair mechanisms has been widely exploited for the treatment of different malignances, including homologous recombination (HR)-deficient breast and ovarian cancers. Here we demonstrate that diffuse large B cell lymphomas (DLBCLs) expressing LMO2 protein are functionally deficient in HR-mediated DSB repair. Mechanistically, LMO2 inhibits BRCA1 recruitment to DSBs by interacting with 53BP1 during repair. Similar to BRCA1-deficient cells, LMO2-positive D  ...[more]

Similar Datasets

Unknown DNA2 nuclease inhibition confers synthetic lethality in cancers with mutant p53 and synergizes with PARP inhibitors.
| S-EPMC10578204 | biostudies-literature
Unknown Inhibition of AURKB, regulated by pseudogene <i>MTND4P12</i>, confers synthetic lethality to PARP inhibition in skin cutaneous melanoma.
| S-EPMC7642665 | biostudies-literature
Unknown Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
| S-EPMC6713455 | biostudies-literature
Proteomics Targeting the ATM-TRMT10A-BRCA1 Axis Confers Synthetic Lethality to PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer
2024-12-30 | PXD059301 |
Unknown PARP inhibitors: Synthetic lethality in the clinic.
| S-EPMC6175050 | biostudies-literature
Unknown Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
| S-EPMC3491838 | biostudies-other
Unknown EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
| S-EPMC5846483 | biostudies-literature
Unknown Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms.
| S-EPMC10743753 | biostudies-literature
Unknown OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.
| S-EPMC9127384 | biostudies-literature
Unknown Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma.
| S-EPMC8962187 | biostudies-literature